Axl-IN-17 

Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC₅₀ value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy^[1].

Axl-IN-17 inhibits cancer-related kinases TYRO3, MER, MET, RON at 1 μM^[1].
Axl-IN-17 exhibits antiproliferative activities in BaF3/TEL-AXL cell, with IC₅₀ value <1 nM^[1].
Axl-IN-17 (1 nM, 2 h) inhibits phosphorylation of AXL and its downstream signaling^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Axl-IN-17 (p.o.,3 mg/kg, once daily) reveals a T_1/2 value of 10.09 h and an AUC value of 59815 ng•h/mL in pharmacokinetic study^[1].
Axl-IN-17 (p.o.,25, 50 or 100 mg/kg, once daily for 7 days) exhibits antitumor efficacy in AXL-driven tumor xenograft mice^[1].

Pharmacokinetic Analysis of AXL-IN-17 in Male Sprague-Dawley rats^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

563.60

C₃₂H₂₇F₂N₇O

3048409-80-6

CC(C)N1C=C(C2=CC=C(F)C=C2)C(C3=C(NC4=CC(F)=C(C5=C(N)N=CC(C6=CN(C)N=C6)=C5)C=C4)N=CC=C31)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lan Y,et al., Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy. Eur J Med Chem. 2024 Feb 5;265:116045.  [Content Brief]